PURPOSE: Retrospective data have demonstrated that breast magnetic resonance imaging (MRI) may change a patient's eligibility for partial breast irradiation (PBI) by identifying multicentric, multifocal, or contralateral disease. The objective of the current study was to prospectively determine the frequency with which MRI identifies occult disease and to establish clinical factors associated with a higher likelihood of MRI prompting changes in PBI eligibility. METHODS AND MATERIALS: At The University of Chicago, women with breast cancer uniformly undergo MRI in addition to mammography and ultrasonography. From June 2009 through May 2011, all patients were screened prospectively in a multidisciplinary conference for PBI eligibility based on standard imaging, and the impact of MRI on PBI eligibility according to National Surgical Adjuvant Breast and Bowel Project protocol B-39/Radiation Therapy Oncology Group protocol 0413 entry criteria was recorded. Univariable analysis was performed using clinical characteristics in both the prospective cohort and in a separate cohort of retrospectively identified patients. Pooled analysis was used to derive a scoring index predictive of the risk that MRI would identify additional disease. RESULTS: A total of 521 patients were screened for PBI eligibility, and 124 (23.8%) patients were deemed eligible for PBI based on standard imaging. MRI findings changed PBI eligibility in 12.9% of patients. In the pooled univariable analysis, tumor size ≥ 2 cm on mammography or ultrasonography (P=.02), age <50 years (P=.01), invasive lobular histology (P=.01), and HER-2/neu amplification (P=.01) were associated with a higher likelihood of MRI changing PBI eligibility. A predictive score was generated by summing the number of significant risk factors. Patients with a score of 0, 1, 2, and 3 had changes to eligibility based on MRI findings in 2.8%, 13.2%, 38.1%, and 100%, respectively (P<.0001). CONCLUSIONS: MRI identified additional disease in a significant number of patients eligible for PBI, based on standard imaging. Clinical characteristics may be useful in directing implementation of MRI in the staging of PBI candidates.
PURPOSE: Retrospective data have demonstrated that breast magnetic resonance imaging (MRI) may change a patient's eligibility for partial breast irradiation (PBI) by identifying multicentric, multifocal, or contralateral disease. The objective of the current study was to prospectively determine the frequency with which MRI identifies occult disease and to establish clinical factors associated with a higher likelihood of MRI prompting changes in PBI eligibility. METHODS AND MATERIALS: At The University of Chicago, women with breast cancer uniformly undergo MRI in addition to mammography and ultrasonography. From June 2009 through May 2011, all patients were screened prospectively in a multidisciplinary conference for PBI eligibility based on standard imaging, and the impact of MRI on PBI eligibility according to National Surgical Adjuvant Breast and Bowel Project protocol B-39/Radiation Therapy Oncology Group protocol 0413 entry criteria was recorded. Univariable analysis was performed using clinical characteristics in both the prospective cohort and in a separate cohort of retrospectively identified patients. Pooled analysis was used to derive a scoring index predictive of the risk that MRI would identify additional disease. RESULTS: A total of 521 patients were screened for PBI eligibility, and 124 (23.8%) patients were deemed eligible for PBI based on standard imaging. MRI findings changed PBI eligibility in 12.9% of patients. In the pooled univariable analysis, tumor size ≥ 2 cm on mammography or ultrasonography (P=.02), age <50 years (P=.01), invasive lobular histology (P=.01), and HER-2/neu amplification (P=.01) were associated with a higher likelihood of MRI changing PBI eligibility. A predictive score was generated by summing the number of significant risk factors. Patients with a score of 0, 1, 2, and 3 had changes to eligibility based on MRI findings in 2.8%, 13.2%, 38.1%, and 100%, respectively (P<.0001). CONCLUSIONS: MRI identified additional disease in a significant number of patients eligible for PBI, based on standard imaging. Clinical characteristics may be useful in directing implementation of MRI in the staging of PBI candidates.
Authors: A Jason Zauls; John M Watkins; Amy E Wahlquist; N Craig Brackett; Eric G Aguero; Megan K Baker; Joseph M Jenrette; Elizabeth Garrett-Mayer; Jennifer L Harper Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-15 Impact factor: 7.038
Authors: Juan Godinez; Eva C Gombos; Sona A Chikarmane; Gabriel K Griffin; Robyn L Birdwell Journal: AJR Am J Roentgenol Date: 2008-07 Impact factor: 3.959
Authors: Lawrence J Solin; Susan G Orel; Wei-Ting Hwang; Eleanor E Harris; Mitchell D Schnall Journal: J Clin Oncol Date: 2008-01-20 Impact factor: 44.544
Authors: Hania A Al-Hallaq; Loren K Mell; Julie A Bradley; Lucy F Chen; Arif N Ali; Ralph R Weichselbaum; Gillian M Newstead; Steven J Chmura Journal: Cancer Date: 2008-11-01 Impact factor: 6.860
Authors: Rahul D Tendulkar; Melanie Chellman-Jeffers; Lisa A Rybicki; Alice Rim; Ashwin Kotwal; Roger Macklis; Betty B Obi Journal: Cancer Date: 2009-04-15 Impact factor: 6.860
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Benjamin D Smith; Douglas W Arthur; Thomas A Buchholz; Bruce G Haffty; Carol A Hahn; Patricia H Hardenbergh; Thomas B Julian; Lawrence B Marks; Dorin A Todor; Frank A Vicini; Timothy J Whelan; Julia White; Jennifer Y Wo; Jay R Harris Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-15 Impact factor: 7.038
Authors: Carolyn E Behrendt; Lusine Tumyan; Laura Gonser; Sara L Shaw; Lalit Vora; I Benjamin Paz; Joshua D I Ellenhorn; John H Yim Journal: Breast Date: 2014-02-14 Impact factor: 4.380
Authors: Rachel Y Lei; Charles E Leonard; Kathryn T Howell; Phyllis L Henkenberns; Timothy K Johnson; Tracy L Hobart; Shannon P Fryman; Jane M Kercher; Jodi L Widner; Terese Kaske; Dennis L Carter Journal: Breast Cancer Res Treat Date: 2013-07-04 Impact factor: 4.872